HEP-16-2287
Saberi et al.
Page 2
Patients with hepatitis C virus (HCV) and hepatocellular carcinoma (HCC) present the unique challenge of when to treat their hepatitis C. In a group of 21 patients with HCV/HCC, we investigated the response to Direct-Acting Antiviral (DAA) drugs prior to receiving a deceased donor liver transplant (LT). Subjects whose HCC was diagnosed on imaging either before or during HCV treatment were included. Seven of the 21 patients (33.3%) relapsed following treatment with various DAA regimens (Table 1A, Table 1S ). Of these seven patients, four were infected with HCV genotype 1A, one genotype 2, and two with genotype 3. In the relapsers, the DAA regimens used were: two with Ledipasvir/Sofosbuvir, one with Simeprevir and Sofosbuvir, and four with Sofosbuvir and Ribavirin (Table 1A) . Subsequently, all of the seven relapsers were transplanted and their explant pathology was carefully reviewed. Six of the seven patients had received loco-regional therapy prior to LT and one had no evidence of viable tumor on the explant. One of the seven had microvascular invasion on explant (Table 2A, Table 2S ). Liver transplants were performed between 2-12 months after the end of treatment with DAAs ( Figure   1 ).
Discussion:
After the development of DAAs, the treatment of HCV has been revolutionized. This article is protected by copyright. All rights reserved.
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tumors with an increase in dropout rates and death. Therefore, prioritizing the management of HCC rather than the hepatitis C in this particular setting should be considered.
One major finding in our series, was the 33% SVR rates which was significantly lower than expected pre-transplant SVR.(4) Our proposed explanation for the lower cure rates in HCC patients may be related to poor penetration of Sofosbuvir drug metabolites into the tumor, as HCC blood supply is from the branches of hepatic artery rather than the portal venous system. This article is protected by copyright. All rights reserved.
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